Introduction and rationale {#sec1}
==========================

Up to 40% of cancer patients develop brain metastases each year in the United States, causing significant morbidity and mortality.[@bib1] Much of the current literature focuses on treatment approaches for brain metastases at initial diagnosis. For many patients stereotactic radiosurgery (SRS) alone, deferring whole brain radiation therapy (WBRT), has become a preferred strategy for small (\<4 cm) metastases and relatively favorable life expectancies.[@bib2], [@bib3], [@bib4]

Phase 3 trials of SRS with or without WBRT for 1 to 3 metastases demonstrated that after SRS alone, local and distant brain failures are approximately 10% to 30% and 40% to 70%, respectively.[@bib5], [@bib6], [@bib7] As systemic therapies improve extracranial disease control, the number of patients who develop new and recurrent brain metastases is likely to increase. Currently, there is no consensus on the optimal treatment for patients with recurrent metastases. Options often include supportive care, repeat SRS, surgery, WBRT, or a combination of these approaches. The evidence regarding the safety and efficacy of the various salvage treatments is very limited.[@bib8] The 2012 American Society for Radiation Oncology brain metastases guidelines did not put forth any recommendations for management of recurrent brain metastases and identified this topic as an area warranting further research.[@bib9]

Given that many patients are treated with additional radiation therapy in the setting of recurrent brain metastases, it is important to consider the benefits of treatment against the risks. One of the most severe side effects of brain radiation therapy is radiation necrosis (RN). The aim of this study was to analyze current salvage practices with respect to risk of developing RN for patients with recurrent brain metastases after initial therapy with SRS. We hypothesized that salvage SRS and/or WBRT under current prescriptive paradigms do not significantly increase the rates of RN.

Methods and materials {#sec2}
=====================

With institutional review board approval, we retrospectively obtained data from electronic medical records of patients treated with SRS alone for primary management of brain metastases between 2001 and 2012. Variables collected included patient age, gender, race, Karnofsky performance status (KPS), tumor histology, extracranial disease burden, as well as number and largest diameter of both initial and recurrent brain metastases. Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis scores were calculated for each patient.[@bib10] Treatment data including radiation modality, prescription doses, and schedules were also obtained.

Initial and repeat SRS without planned WBRT was generally offered for \<5 brain metastases, each \<4 cm, in patients with KPS ≥70, and life expectancies ≥3 months. If additional occult metastases were found at the time of SRS, ≥5 lesions were sometimes treated with SRS with or without WBRT. Patients who received SRS to the same lesion multiple times were excluded given previously demonstrated elevated risk of RN.[@bib11] WBRT was not combined with initial or salvage SRS but was used as a separate salvage therapy. Although there was no strict standard for use of salvage WBRT, it was generally used for patients with \>4 active lesions, Eastern Cooperative Oncology Group performance scale ≥2, or predicted life expectancy of \<3 months. Salvage surgery was typically reserved for patients with large (\>4 cm) or severely symptomatic lesions.

SRS was performed using a Leksell Gamma Knife Model C (Elekta AB, Stockholm, Sweden). The target volume included the contrast-enhancing lesion with a 1 to 2 mm margin. Prescription doses were generally based on tumor size according to RTOG study 90-05.[@bib12] Prescription doses for salvage WBRT ranged from 20 to 37.5 Gy in 10 to 15 fractions.

Patients were seen in follow-up approximately 1 month after treatment and every 3 months thereafter. Magnetic resonance imaging scans were obtained at each scheduled visit. The primary outcome measure for this study was rate of RN. RN was either confirmed by pathology after surgical resection or defined as a symptomatic patient with magnetic resonance spectroscopy or perfusion results consistent with necrosis. Patients were grouped according to salvage treatment received. Potential variables affecting incidence of necrosis were compared via Fisher\'s exact tests. Two-sided *P* values \<.05 were considered statistically significant.

Results {#sec3}
=======

A total of 284 patients with 677 total brain metastases treated with initial SRS alone were included. The demographic data for these patients are presented in [Table 1](#tbl1){ref-type="table"}. No salvage treatments were delivered to 152 patients (53.5%), whereas 132 patients (46.5%) experienced in brain failure and received salvage therapy. Forty-four (15.5%) received multiple salvage treatments. Of the salvaged patients, 31 (23.5%) underwent 1 or more SRS treatments without WBRT, 58 (43.9%) WBRT alone, 28 (21.2%) SRS and WBRT delivered as separate salvage therapies, 7 (0.5%) underwent surgery alone, and 8 (0.6%) surgery with adjuvant radiation (5 adjuvant SRS, 3 adjuvant WBRT).Table 1Patient demographics at initial SRSTable 1VariableCategoryAll patients (N = 284)Salvaged patients (N = 132)Never salvaged patients (N = 152)SexMale130 (46%)58 (44%)71 (47%)Female154 (54%)74 (56%)81 (53%)Age at first SRSMedian61.659.763.5HistologyNon-small cell lung174 (61%)84 (64%)90 (59%)Breast32 (12%)23 (17%)9 (6%)Melanoma20 (7%)8 (6%)12 (8%)Colon7 (2%)3 (2%)4 (3%)Other51 (18%)14 (11%)37 (24%)RPA class169 (25%)44 (33%)31 (20%)2187 (66%)69 (52%)111 (73%)Unknown25 (9%)15 (11%)7 (5%)Number of lesionsAverage332Range1-141-121-14Maximum lesion size, cm^3^Average9.876.207.66Range0.1-93.290.27-93.290.27-64.45Prescription dose (minimum dose delivered to largest met), GyAverage18.6318.3718.91Range12-2212-2212-22[^1]Table 2Comparative analysis of salvage treatments and associations with risk of radiation necrosisTable 2GroupOR for RN with 95% CI*P* valueAny salvage vs no salvage2.37 (0.56-9.65).31Salvage SRS vs any salvage2.32 (0.72-7.49).21Salvage WBRT vs any salvage1.59 (0.49-5.09).55Salvage surgery vs any salvage0.63 (0.03-11.69).76Any salvage vs salvage SRS + WBRT5.73 (1.69-19.38)**.0075**Salvage SRS vs salvage SRS + salvage WBRT18.2 (0.98-339.79)**.05**Salvage WBRT vs salvage SRS + salvage WBRT3.77 (1.11-12.85)**.04**Salvage SRS alone vs salvage WBRT alone1.86 (0.034-95.86).31SubgroupsAll salvage WBRT dose ≥30 vs \<304 (0.69-23.23).18All SRS lesions \>4 vs 1-43.24 (0.35-29.58).39[^2][^3]

With a median follow-up of 10 months, the rate of RN among all patients was 3.17% (9/284), never salvaged patients 1.97% (3/152), and salvaged patients 4.55% (6/132). RN was confirmed by pathology in 7/9 (78%) of these patients, and suggested by symptomatology and magnetic resonance spectroscopy or perfusion in 2/9 (22%) patients. Receiving salvage therapy did not significantly increase risk of RN (*P* = .31). These data are depicted in [Fig 1](#fig1){ref-type="fig"}.Figure 1Effect of salvage treatment on radiation necrosis (RN) incidence.Figure 1

Subgroup analysis according to salvage approach revealed the highest rate of necrosis in patients that had both salvage SRS and salvage WBRT (6/28 or 21.42%). RN in this group was significantly more frequent than those receiving no salvage therapy (3/152, *P* \< .001), salvage SRS alone (0/31, *P* \< .001), and salvage WBRT alone (0/58, *P* \< .001). The RN rate was not significantly greater than that in patients who underwent salvage surgery alone (0/7, *P* = .311), or salvage surgery with adjuvant radiation (0/8, *P* = .302), likely because of small sample sizes in these groups. RN incidence between patients that underwent salvage SRS alone and salvage WBRT alone was also not significantly different (*P* = 1.0). These data are graphed in [Fig 2](#fig2){ref-type="fig"}.Figure 2Incidence of RN by salvage modality. RN, radiation necrosis; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy.Figure 2

To assess whether dose of salvage WBRT contributed to rate of RN, patients that received doses of \<30 Gy were compared with those that received ≥30 Gy. No significant effect of dose on incidence of RN was found (*P* = .181). Additionally, among patients who received multiple SRS treatments, number of treated lesions was not predictive of RN incidence (*P* = .3982). Size analysis in this population revealed no significant effect of volume of largest met \<5 cm^3^ versus ≥5 cm^3^ on incidence of RN (*P* = .4168.) Patients who received SRS for \>4 cumulative lesions had a risk of RN of 12.8%, whereas patients that were treated to ≤4 lesions had a risk of RN of 4.3%. These data are depicted in [Fig 3](#fig3){ref-type="fig"}. Primary and subgroup comparisons are given in [Table 2](#tbl2){ref-type="table"}.Figure 3Risk of RN by cumulative dose. Abbreviations as in [Fig 2](#fig2){ref-type="fig"}.Figure 3

Discussion {#sec4}
==========

Limited data exist to guide salvage treatment decisions for patients with recurrent brain metastases after initial management with SRS alone. Management is typically individualized and based on a variety of factors including patient KPS, extracranial disease status, prior treatment history, and recurrent lesion size, number, timing, and location.[@bib13] Given that many of these patients are treated with multiple courses of radiation therapy (ie, repeat SRS and/or salvage WBRT), risk of additional radiation-related toxicity must be considered.

The present study investigated risk of RN, the most common and serious late complication after SRS. RN is permanent brain injury that manifests 3 months to several years after treatment. Although the exact pathogenesis of RN is unknown, it is thought to involve release of pro-inflammatory cytokines, vascular damage, and direct toxicity to neuroglia.[@bib14], [@bib15] In the absence of invasive pathological confirmation, RN is often difficult to distinguish from temporary adverse radiation effects (ARE) and tumor progression. Both RN and tumor recurrence can cause progressive clinical deterioration and death.[@bib16] Advanced magnetic resonance imaging sequences, magnetic resonance spectroscopy, and magnetic resonance perfusion are most commonly used to help differentiate RN from recurrent tumor.[@bib17], [@bib18], [@bib19] Our group defined RN by pathology after resection or symptomatic ARE with magnetic resonance spectroscopy and/or perfusion consistent with RN. With this definition, the incidence of RN in our entire cohort of SRS treated patients was 3%. This is consistent with other studies which have demonstrated RN risk of approximately 5% after SRS for brain metastases.[@bib20], [@bib21]

The incidence of RN is directly related to total radiation dose, volume, and fraction size.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32] RTOG 90-05 established that for patients who had previously received irradiation for primary brain tumors or brain metastases, maximum tolerated dose of single-fraction SRS was 24 Gy, 18 Gy, and 15 Gy for tumors ≤20 mm, 21 to 30 mm, and 31 to 40 mm in maximum diameter, respectively, with larger tumor diameter predictive of greater central nervous system (CNS) toxicity.[@bib12] Incidence of RN in RTOG 90-05 was 5% at 6 months after SRS, and increased incrementally with time thereafter, up to 11% at 24 months.[@bib33] In the setting of SRS without WBRT, the volumes of CNS tissue that receives 10 and 12 Gy have been consistently shown to correlate with risk of RN.[@bib23], [@bib28], [@bib34] In addition to 10- and 12-Gy volumes, Sneed et al identified capecitabine/fluorouracil use within 1 month and prior SRS to the same lesion as other independent predictors of ARE after SRS. For locally recurrent metastases treated with repeat SRS, the risk of symptomatic ARE was approximately 20% at 1 year.[@bib35] A rate of 19% was seen for patients treated repeat SRS to the same lesion.[@bib11] We therefore excluded these patients from our study. We hypothesized, however, that other salvage practices under current prescriptive paradigms would not be associated with elevated risk of RN given that SRS doses used were established by RTOG 90-05, which, as previously noted, determined maximum tolerated SRS dose in previously irradiated patients.[@bib12]

As predicted, we found that after initial SRS, treating recurrences with salvage SRS alone, WBRT alone, or surgery with adjuvant radiation were not associated with increased risk of RN. However, when repeat SRS was combined with WBRT, more than 20% of patients developed RN. This increased risk of RN is likely due to relatively higher radiation doses to larger volumes of normal brain tissue in these patients. Our results, thus, suggest that if a patient is felt to likely need salvage WBRT, combining this with additional SRS treatments might have risks that outweigh the benefits of repeat SRS. Therefore, it would be useful to estimate risk of regional recurrence and likelihood for future salvage WBRT before offering patients repeat SRS.

Multiple tools have been developed that predict for overall survival in patients with brain metastases.[@bib10], [@bib36], [@bib37], [@bib38] The Graded Prognostic Assessment has recently been shown to also predict survival in the salvage SRS setting.[@bib39] Variables, such as patient age, KPS, cancer histology, number of metastases, and systemic disease status, which predict for regional brain failure and WBRT-free survival after initial SRS, are also likely useful in the context of salvage treatments.[@bib40], [@bib41], [@bib42], [@bib43] In our study, only 30% (86/284) of patients treated with upfront SRS required salvage WBRT; however, a significant portion of patients (47.5%; 28/59) treated with repeat SRS eventually needed WBRT. Methods are needed to optimize patient selection for salvage SRS to avoid treating patients that will require early WBRT with its associated toxicities.

The interpretation of our results is limited by the retrospective nature and nonrandomized study design, which introduces multiple well-described biases in data collection and analysis.[@bib44] This could have led to the underestimation of incidence of RN in our patient population. Additionally, the generalizability of our results is dependent on how one defines RN. In patients without surgical removal of necrotic tissue, we had a high threshold to consider radiographic findings as consistent with RN. It is possible that some patients with RN were not identified because of loss of follow-up or because magnetic resonance spectroscopy or perfusion studies were simply not obtained. More accurate methods of distinguishing RN from temporary ARE or tumor progression is an area of active research.

Conclusion {#sec5}
==========

Our results suggest that initial management approach for recurrent brain metastasis after upfront SRS alone does not affect the rate of subsequent RN. However, when patients are treated with repeat SRS and salvage WBRT, risk of RN significantly increases. When faced with recurrent brain metastases, patient and disease factors, as well as likelihood of requiring additional salvage treatment, are important considerations when estimating potential benefits and risks of therapy.
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